A Maturing Amgen Focuses On Capital Allocation, Late-Stage Pipeline
Even as it reaffirms its big long-term bet on R&D, Amgen appeases investors with tweaks to its R&D organization and expansion of its share buyback program.
Even as it reaffirms its big long-term bet on R&D, Amgen appeases investors with tweaks to its R&D organization and expansion of its share buyback program.